Frank Buchholz and Seamless Therapeutics GmbH on designer recombinases competing with CRISPR

In our latest news release, Frank Buchholz (TU Dresden) and Anne-Kristin Heninger (Seamless Therapeutics GmbH) look at how designer recombinases have become a strong competitor of CRISPR. Explaining their research, Frank and Anne also reflect on the enormous potential of designer recombinases.

Please find the complete MIT Technology Review article here (PDF, German).